Anatole Besarab

Summary

Affiliation: Division of Nephrology and Hypertension
Country: USA

Publications

  1. ncbi Resolving the paradigm crisis in intravenous iron and erythropoietin management
    A Besarab
    Henry Ford Hospital, 2799 West Grand Blvd, CFP511, Detroit, Michigan 48202, USA
    Kidney Int Suppl . 2006
  2. ncbi Optimizing anaemia management with subcutaneous administration of epoetin
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, CFP 511, 2799 West Grand Boulevard, Detroit, MI 48201, USA
    Nephrol Dial Transplant 20:vi10-5. 2005
  3. ncbi Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
    Anatole Besarab
    Division of Nephrology and Hypertension, Department o f Medicine, Henry Ford Hospital, Detroit, Michigan, USA
    Clin Ther 29:626-39. 2007
  4. ncbi More than a decade of experience and still no consensus: controversies in iron therapy
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Clin J Am Soc Nephrol 1:S1-3. 2006
  5. ncbi Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients?
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Nat Clin Pract Nephrol 1:70-1. 2005
  6. ncbi Anemia management in chronic heart failure: lessons learnt from chronic kidney disease
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Kidney Blood Press Res 28:363-71. 2005
  7. ncbi Access monitoring is worthwhile and valuable
    Anatole Besarab
    Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI 48301, USA
    Blood Purif 24:77-89. 2006
  8. ncbi Vascular access: issues and management
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Mich, USA
    Contrib Nephrol 142:29-46. 2004
  9. ncbi What common practices in dialysis units can be altered to improve patient care?
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan 48201, USA
    Semin Dial 17:16-7. 2004
  10. doi Automated intravascular access pressure surveillance reduces thrombosis rates
    Gerard Zasuwa
    Division of Nephrology and Hypertension, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Semin Dial 23:527-35. 2010

Detail Information

Publications49

  1. ncbi Resolving the paradigm crisis in intravenous iron and erythropoietin management
    A Besarab
    Henry Ford Hospital, 2799 West Grand Blvd, CFP511, Detroit, Michigan 48202, USA
    Kidney Int Suppl . 2006
    ..v. iron dosing on a regular basis in the hemodialysis patient with iron-deficiency anemia and explores reasons why some clinicians may still be reluctant to employ these protocols in the hemodialysis setting...
  2. ncbi Optimizing anaemia management with subcutaneous administration of epoetin
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, CFP 511, 2799 West Grand Boulevard, Detroit, MI 48201, USA
    Nephrol Dial Transplant 20:vi10-5. 2005
    ..c. administration. The reduced dose with s.c. administration of epoetin-beta provides significant cost benefits, without compromising either safety or efficacy, and may also increase patient satisfaction and compliance with treatment...
  3. ncbi Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
    Anatole Besarab
    Division of Nephrology and Hypertension, Department o f Medicine, Henry Ford Hospital, Detroit, Michigan, USA
    Clin Ther 29:626-39. 2007
    ..A continuous erythropoietin receptor activator (C.E.R.A.) is currently in development for the treatment of anemia in patients with chronic renal disease (CRD) receiving or not receiving dialysis treatment...
  4. ncbi More than a decade of experience and still no consensus: controversies in iron therapy
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Clin J Am Soc Nephrol 1:S1-3. 2006
  5. ncbi Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients?
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Nat Clin Pract Nephrol 1:70-1. 2005
  6. ncbi Anemia management in chronic heart failure: lessons learnt from chronic kidney disease
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Kidney Blood Press Res 28:363-71. 2005
    ..In addition to the currently available evidence, additional large, randomized, controlled studies are required to further define the morbidity/mortality benefits of epoetin treatment in CHF patients with anemia...
  7. ncbi Access monitoring is worthwhile and valuable
    Anatole Besarab
    Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI 48301, USA
    Blood Purif 24:77-89. 2006
    ....
  8. ncbi Vascular access: issues and management
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Mich, USA
    Contrib Nephrol 142:29-46. 2004
  9. ncbi What common practices in dialysis units can be altered to improve patient care?
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan 48201, USA
    Semin Dial 17:16-7. 2004
  10. doi Automated intravascular access pressure surveillance reduces thrombosis rates
    Gerard Zasuwa
    Division of Nephrology and Hypertension, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Semin Dial 23:527-35. 2010
    ..We conclude that use of VAPRT can reduce thrombosis rates in vascular accesses, and the magnitude of the effect is larger and more consistent in arteriovenous grafts (AVGs) than autologous AVFs...
  11. ncbi Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
    Am J Kidney Dis 40:439-46. 2002
    ....
  12. ncbi Utility of static pressure ratio recording during angioplasty of arteriovenous graft stenosis
    Arif Asif
    Division of Nephrology, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
    Semin Dial 19:551-6. 2006
    ..33 +/- 0.02). Qa increased significantly in 74 of 83 (89%) procedures (before = 572 +/- 201, after = 1109 +/- 368 ml/min; p < 0.001). SPR measurements can assist in hemodynamic assessment of an AVG during angioplasty procedure...
  13. doi Hemoglobin variability and hyporesponsiveness: much ado about something or nothing?
    Jerry Yee
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202 2689, USA
    Adv Chronic Kidney Dis 16:83-93. 2009
    ..Finally, integration of all of these concepts is possible within the context of an anemia management protocol...
  14. doi What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202 2699, USA
    Adv Chronic Kidney Dis 16:131-42. 2009
    ..For the individual patient, the therapeutic decision should center on what Hb is most appropriate at a "safe" ESA dose. Consequently, an Hb of 12 to 13 g/dL may be totally appropriate in some patient populations...
  15. ncbi Interventional nephrology: from episodic to coordinated vascular access care
    Arif Asif
    Division of Nephrology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    J Nephrol 20:399-405. 2007
    ..Challenges for the future include awareness of this subspecialty and development of training programs at academic centers on a larger scale...
  16. ncbi Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia
    Uday S Nori
    Division of Nephrology, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 48:596-605. 2006
    ..We hypothesized that a low concentration of gentamicin would be as effective as the high doses studied in the past...
  17. ncbi Dynamic venous access pressure ratio test for hemodialysis access monitoring
    Stanley Frinak
    Department of Medicine, Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 40:760-8. 2002
    ..We developed a method to prospectively monitor AVGs that uses an algorithm to calculate venous access pressure (VAP) during HD from the venous drip chamber pressure (VDP)...
  18. ncbi Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia
    Nizar Attallah
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 47:644-54. 2006
    ..We conducted an open-label prospective study to assess the effect of vitamin C, an antioxidant, on EPO-hyporesponsive anemia in hemodialysis patients with unexplained hyperferritinemia...
  19. pmc Managing anemia in patients with chronic heart failure: what do we know?
    Ankur Sandhu
    Division of Nephrology, Henry Ford Health System, Detroit, Michigan 48202, USA
    Vasc Health Risk Manag 6:237-52. 2010
    ....
  20. ncbi Vascular access for hemodialysis: 2004 and beyond
    Prakas T D'Cunha
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan, USA
    Curr Opin Nephrol Hypertens 13:623-9. 2004
    ..Preoperative mapping to evaluate veins and artery may permit construction of arteriovenous fistula in up to 70% of all patients, thereby reducing access thrombosis, infection, and perhaps increasing survival of patients...
  21. doi Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome
    Anatole Besarab
    Wayne State University, Detroit, Michigan, USA
    Oncologist 14:22-33. 2009
    ..In such patients, correction of anemia appears to improve cardiac function and quality of life without a greater risk for adverse events...
  22. doi Candidate biomarkers for erythropoietin response in end-stage renal disease
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Kidney Int 79:488-90. 2011
    ..This maneuver requires weeks to months. The study by Merchant et al. offers promise that peptidomic analyses of patient sera and mass spectrometry can identify biomarkers of both responsiveness and resistance to ESAs...
  23. ncbi Vascular mapping techniques: advantages and disadvantages
    Arif Asif
    Division of Nephrology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida 3136, USA
    J Nephrol 20:299-303. 2007
    ..This article presents advantages and disadvantages of the 3 mapping techniques and proposes a strategy to conduct vascular mapping in patients with chronic kidney disease...
  24. pmc An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients
    Anatole Besarab
    Henry Ford Hospital, Detroit, MI, USA
    BMC Nephrol 13:95. 2012
    ..0 g/dL of baseline values after conversion from epoetin alfa; the safety of peginesatide was evaluated concurrently...
  25. pmc Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy
    Lenar Yessayan
    Division of Nephrology and Hypertension, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Int J Nephrol 2013:703038. 2013
    ..Of 1699 iron dextran infusions, three ADEs occurred. Conclusions. Treatment of anemia in CKD stages 3 and 4 with LMWID and darbepoetin is efficacious. The serious ADE rate was 0.06% per infusion...
  26. doi Iron supplementation to treat anemia in patients with chronic kidney disease
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48301, USA
    Nat Rev Nephrol 6:699-710. 2010
    ..This Review examines the efficacy, safety and use of iron supplementation therapy for the treatment of anemia in patients with CKD...
  27. ncbi Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets
    Steven Fishbane
    Division of Nephrology, Department of Medicine, Winthrop University Hospital, Mineola, New York, USA
    Clin J Am Soc Nephrol 2:1274-82. 2007
    ....
  28. ncbi Biology of arteriovenous fistula failure
    Prabir Roy-Chaudhury
    Division of Nephrology and Hypertension, University of Cincinnati, Cincinnati, Ohio 45267 0585, USA
    J Nephrol 20:150-63. 2007
    ..Finally, we will end with a brief description of some state-of-the-art clinical trials that are attempting to apply some of these novel therapeutic concepts to the recalcitrant clinical problem of AV fistula failure...
  29. ncbi Iron sucrose: the oldest iron therapy becomes new
    Jerry Yee
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 40:1111-21. 2002
    ..Management of patients with the anemia of CKD mandates that we carefully examine the effectiveness and safety of this oldest of iron preparations and the accumulating present-day data regarding it and contemporaneous agents...
  30. ncbi Preventing vascular access dysfunction: which policy to follow
    Anatole Besarab
    Division of Nephrology, Department of Medicine, University of West Virginia School of Medicine, Morgantown, WV, USA
    Blood Purif 20:26-35. 2002
    ..Strategies and resources needed to achieve these policies are presented. The need for a team approach is emphasized...
  31. pmc Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study
    Lenar Yessayan
    Division of Nephrology and Hypertension, Henry Ford Hospital, 2799 W, Grand Blvd, CFP 514, Detroit, MI, USA
    BMC Nephrol 15:119. 2014
    ..We investigated the effect of intravenous iron repletion on platelet counts in ND-CKD patients with and without concomitant darbepoetin administration...
  32. doi Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis. Pro
    Anatole Besarab
    Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI 48301, USA
    J Am Soc Nephrol 19:1629-31. 2008
    ..Here the various positions are examined from multiple perspectives...
  33. ncbi Antimicrobial locks: putting the lock on catheter infections
    Carol Manierski
    Department of Nephrology and Hypertension, Henry Ford Health System, Detroit, MI 48202, USA
    Adv Chronic Kidney Dis 13:245-58. 2006
    ..The objectives of this review are to evaluate the current body of evidence espousing the utilization of an antimicrobial lock solution in tunneled cuffed and uncuffed catheters that are utilized during chronic intermittent hemodialysis...
  34. ncbi Effect of differing blood lines on delivered blood flow during hemodialysis
    Junaid Ahmed
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 44:498-508. 2004
    ..BACKGROUND The influence of differing blood tubing sets on delivered dialyzer blood flow (Q B ) was studied using ReadySet (RS; Medisystem Inc, Seattle, WA) and CombiSet (CS; Fresenius, Walnut Creek, CA)...
  35. doi Catheter management in hemodialysis patients: delivering adequate flow
    Anatole Besarab
    Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Clin J Am Soc Nephrol 6:227-34. 2011
    ..Wherever possible we note the areas in which there is scant data where further randomized clinical trials are needed...
  36. ncbi How can the cardiac death rate be reduced in dialysis patients?
    Anatole Besarab
    Department of Medicine, Robert C Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia 26506, USA
    Semin Dial 15:24-6. 2002
  37. doi A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial
    Dennis G Maki
    Department of Medicine, Section of Infectious Diseases, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Crit Care Med 39:613-20. 2011
    ..Catheter-related bloodstream infection is the greatest threat to the safety of patients on hemodialysis. Catheter lock solutions containing heparin have been linked to an increased risk of hemorrhage and thrombocytopenia...
  38. ncbi Recommended standards for reports dealing with arteriovenous hemodialysis accesses
    Anton N Sidawy
    Committee on Reporting Standards for Arterio Venous Accesses of The Society for Vascular Surgery and the American Association for Vascular Surgery, Washington, DC, USA
    J Vasc Surg 35:603-10. 2002
    ....
  39. ncbi Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines
    Hugh C Rayner
    Birmingham Heartlands Hospital, United Kingdom
    Am J Kidney Dis 44:22-6. 2004
    ..They recommend letting fistulae mature > or =1 month before cannulation...
  40. ncbi Regional variability in anaemia management and haemoglobin in the US
    Donal N Reddan
    Duke Institute of Renal Outcomes Research and Health Policy, Duke University Medical Center, Durham, NC 27710, USA
    Nephrol Dial Transplant 18:147-52. 2003
    ..It was posited that regional differences in haemoglobin values are consequent upon differences in components of clinical practice...
  41. ncbi Changes noted to KDOQI guidelines for vascular access
    Anatole Besarab
    Kidney Disease Outcomes Quality Initiative Workgroup for Vascular Access
    Nephrol News Issues 20:36. 2006
  42. ncbi Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial
    Marian Klinger
    Department of Nephrology and Transplantation Medicine, Medical University, Wroclaw, Poland
    Am J Kidney Dis 50:989-1000. 2007
    ..We examined its efficacy for Hb level correction when administered once every 2 weeks in erythropoiesis-stimulating agent-naive dialysis patients...
  43. doi The normal hematocrit study--follow-up
    Anatole Besarab
    N Engl J Med 358:433-4. 2008
  44. ncbi New developments in anemia management in chronic kidney disease
    Richard Amerling
    Beth Israel Medical Center NewYork, NewYork, USA
    Nephrol News Issues 22:suppl 1-8. 2008
  45. pmc Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients
    Ryan D Kilpatrick
    Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
    Clin J Am Soc Nephrol 3:1077-83. 2008
    ..Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated...
  46. ncbi A randomized controlled trial of oral versus intravenous iron in chronic kidney disease
    Rajiv Agarwal
    Indiana University School of Medicine, Richard L Roudebush VA Medical Center, Indianapolis, IN 46202, USA
    Am J Nephrol 26:445-54. 2006
    ..We conducted a randomized multicenter controlled trial in adult anemic, iron-deficient non-dialysis CKD (ND-CKD) patients (>or=stage 3) not receiving erythropoiesis-stimulating agents (ESAs)...
  47. ncbi Clinical epidemiology of arteriovenous fistula in 2007
    Pietro Ravani
    Clinical Epidemiology Unit, Memorial University of Newfoundland, St John s, Newfoundland, Canada
    J Nephrol 20:141-9. 2007
    ..Recent experience from the United States suggests that multidisciplinary management is the most appropriate approach to deal with all the multifaceted aspects of end-stage renal disease care and to increase the likelihood of success...
  48. ncbi Surgical salvage of the autogenous arteriovenous fistula (AVF)
    Lawrence M Spergel
    Dialysis Management Medical Group, San Francisco, CA 94109, USA
    J Nephrol 20:388-98. 2007
    ..These include strategies to salvage primary failed fistulae due to early thrombotic events or lack of maturation, ischemia, venous hypertensive problems, aneurysms and infections...
  49. ncbi Autogenous arteriovenous fistula options
    Lawrence M Spergel
    Dialysis Management Medical Group, San Francisco, California 94109, USA
    J Nephrol 20:288-98. 2007
    ..Optimizing autogenous options for hemodialysis requires vessel mapping and a surgeon's willingness to invest additional time and effort...